Eye diseases
22 public biotech companies we cover are developing treatments for retinal disease, macular degeneration, uveitis and other eye conditions. 27 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Akebia Therapeutics (AKBA)Thesis Intact
Retinopathy of prematurity
- Alumis (ALMS)Thesis Challenged
Thyroid eye disease
- ANI Pharmaceuticals (ANIP)Thesis Challenged
Diabetic macular edema, Non-infectious uveitis of the posterior segment, Chronic non-infectious uveitis affecting posterior segment
- Annexon (ANNX)Thesis Intact
Geographic atrophy, Dry AMD with geographic atrophy
- Ascendis Pharma (ASND)Thesis Challenged
Wet AMD and other retinal diseases
- Belite Bio (BLTE)Thesis Intact
Stargardt disease, Geographic atrophy, Stargardt disease type 1 (STGD1)
- BioAge Labs (BIOA)Thesis Intact
Diabetic macular edema
- Design Therapeutics (DSGN)Thesis Intact
Fuchs Endothelial Corneal Dystrophy
- Entrada Therapeutics (TRDA)Thesis Intact
Usher syndrome type 2A, Inherited retinal disease
- Harrow (HROW)Thesis Challenged
Wet AMD, Uveitis, Glaucoma, Ocular pain, and 10 more
- Kiora Pharmaceuticals (KPRX)Thesis Intact
Macular edema, Choroideremia, Stargardt disease, Retinitis Pigmentosa, and 4 more
- Kodiak Sciences (KOD)Thesis Challenged
Glaucoma, Macular edema, Geographic atrophy, Ocular inflammation, and 5 more
- Lineage Cell Therapeutics (LCTX)Thesis Intact
Vision loss, Geographic atrophy, Bullous Keratopathy, Fuchs Endothelial Corneal Dystrophy
- MeiraGTx (MGTX)Thesis Intact
Leber congenital amaurosis, X-linked retinitis pigmentosa
- Ocugen (OCGN)Thesis Intact
Stargardt disease, Geographic atrophy, Retinitis pigmentosa, Diabetic macular edema, and 1 more
- Ocular Therapeutix (OCUL)Thesis Intact
Open-angle glaucoma, Diabetic retinopathy, Allergic conjunctivitis, Wet age-related macular degeneration, and 1 more
- OKYO Pharma (OKYO)Thesis Intact
Dry eye disease, Neuropathic Corneal Pain
- Opus Genetics (IRD)Thesis Intact
Presbyopia, Bestrophinopathy, Visual disturbances, Retinitis pigmentosa, and 11 more
- Palatin Technologies (PTN)Thesis Challenged
Dry eye disease, Diabetic retinopathy, Diabetic macular edema
- Roivant Sciences (ROIV)Thesis Intact
Non-infectious uveitis
- Stoke Therapeutics (STOK)Thesis Intact
Autosomal Dominant Optic Atrophy
- Viridian Therapeutics (VRDN)Thesis Intact
Thyroid eye disease
Drug pages
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Later
- Feb 12in 110 daysTinlarebant · FDA decision · Stargardt disease (STGD1)
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in October 2026
- October 2026Phentolamine Ophthalmic Solution · Phase 3 topline results (LYNX-3) · Visual disturbances · post-keratorefractive surgery · mesopic, low-contrast conditions
Expected by end of November 2026
- late 2026KIO-104 · Interim results · Macular edema · retinal inflammation
Expected in December 2026
- December 2026KSI-101 · Phase 3 topline results (PEAK) · Macular Edema Secondary to Inflammation (MESI)
Expected in Q4 2026
- Q4 2026ILUVIEN · Phase 4 topline results (SYNCHRONICITY) · Chronic non-infectious uveitis affecting posterior segment
- Q4 2026ANX007 · Phase 2 topline results (ARCHER) · Dry AMD with geographic atrophy
- Q4 2026NATACYN · Topline results · Fungal keratitis
- Q4 2026OPGx-RDH12 · Phase 1/2 start · RDH12-related Leber congenital amaurosis (LCA) · inherited retinal degeneration
- Q4 2026Zenkuda · BLA submission · Wet Age-Related Macular Degeneration · Diabetic Retinopathy · Retinal Vein Occlusion
- Q4 2026AXPAXLI · NDA submission · Wet AMD
- Q4 2026TSHR · IND submission · Thyroid eye disease
Expected by end of 2026
- By year-end 2026COR1 · Preclinical results · Fuchs Endothelial Corneal Dystrophy · Bullous Keratopathy
- By year-end 2026Bota-vec · Regulatory submission · X-linked retinitis pigmentosa
- year-end 2026STK-002 · Phase 1 enrollment complete (OSPREY) · Autosomal Dominant Optic Atrophy
Expected in Q1 2027
- Q1 2027OPGx-MERTK · Trial start · MERTK-related retinal degeneration · inherited retinal disease
- Q1 2027OCU400 · Phase 3 topline results (liMeliGhT) · Retinitis pigmentosa
- Q1 2027Elegrobart · BLA submission · Thyroid eye disease
Expected by end of March 2027
- Early 2027TRIESENCE · Phase 3 topline results · Ocular inflammation and pain · post-cataract surgery
Expected in Q2 2027
- Q2 2027OPGx-BEST1 · Phase 1/2 topline results (BIRD-1) · BEST1-related retinal degeneration · Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
- Q2 2027KSI-101 · Phase 3 topline results (PEAK/PINNACLE) · Macular Edema Secondary to Inflammation
- Q2 2027KSI-101 · BLA submission · Macular Edema Secondary to Inflammation
- Q2 2027OCU400 · BLA submission · Retinitis pigmentosa
- Q2 2027OCU410ST · Confirmatory Phase 2/3 topline results (GARDian3) · Stargardt disease · ABCA4-associated retinopathies
Expected in H1 2027
- H1 2027Brepocitinib · sNDA submission · Non-infectious uveitis
- H1 2027STK-002 · Phase 1 results (OSPREY) · Autosomal Dominant Optic Atrophy
Expected by end of June 2027
- Mid-2027OCU410ST · BLA submission · Stargardt disease · ABCA4-associated retinopathies
Expected in Q3 2027
- Q3 2027KIO-301 · Phase 2 topline results (ABACUS-2) · Retinitis Pigmentosa